Overview

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

Status:
Unknown status

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled trial to evaluate the clinical benefit of palifosfamide tris administered with doxorubicin in combination, compared with single-agent doxorubicin administered in subjects diagnosed with unresectable or metastatic soft-tissue sarcoma (STS). Subjects who meet the entry criteria will be randomized into 1 of 2 arms: either to receive palifosfamide tris plus doxorubicin or treatment with single-agent doxorubicin. Subjects will be anthracyclin naïve.

Phase:

Phase 2

Details

Lead Sponsor:

Ziopharm

Treatments:

Doxorubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin